Background: The identification of biomarkers identifying onset of human immunodeficiency virus-associated dementia (HIV-D) is critical for diagnosis and the elucidation of pathophysiologic pathways.
Objective: To examine the association between platelet decline from baseline and HIV-D.
Design: Prospective cohort study within the North-East AIDS Dementia cohort.
Setting: Four participating referral centers in the United States.
Participants: A total of 396 subjects with advanced human immunodeficiency virus (HIV) infection recruited between 1998 and 2003 and undergoing serial neurologic assessments. Eligibility criteria required CD4 cell counts less than 200/microL or less than 300/microL with evidence of cognitive impairment. A cohort subset without prevalent HIV-D at baseline and without incident HIV-D at the visit immediately after baseline was analyzed (n = 146). Main Outcome Measure Time to first diagnosis of HIV-D.
Results: After a median follow-up of 31.1 months, 40 subjects developed HIV-D. Platelet decline from baseline was associated with the development of HIV-D when examined as a time-dependent variable lagged by 6 to 12 months before outcome (multivariate hazard ratio [HR], 2.39; 95% confidence interval [CI], 1.14-5.02; P = .02). This association was stronger during the first 2 years of follow-up (multivariate HR, 6.76; 95% CI, 2.36-19.41; P < .001) than during later years (multivariate HR, 0.94; 95% CI, 0.33-2.67; P = .90).
Conclusions: These results suggest that individuals with declining platelet counts are at greater risk for HIV-D and that the dynamics of circulating platelets vary with respect to the temporal progression of HIV-D. This highlights an avenue to be explored in the understanding of HIV-D pathogenesis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/archneur.64.9.1264 | DOI Listing |
Transl Androl Urol
November 2024
Department of Urology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Background And Objective: The treatment of prostate cancer (PCa) often comes with the risk of erectile dysfunction (ED). As therapeutic technologies continue to advance, the incidence of ED and its treatment methods are also evolving. This paper aimed to provide a comprehensive analysis of the latest developments in PCa treatment, with a particular focus on its relationship with ED, and to review current innovative strategies for ED treatment.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
Department of Cardiac Surgery, First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan II Rd, Guangzhou, 510080, China.
Background: This study aimed to summarize the pathogenic spectrum of infective endocarditis (IE) and analyze the risk factors for poor prognosis in surgical patients in a tertiary hospital in China.
Methods: We retrospectively included patients diagnosed with IE between January 2013 and January 2022. The pathogenic spectrum was summarized; the risk factors for early postoperative mortality and embolic events were analyzed using multivariate logistic regression.
Medicine (Baltimore)
December 2024
Department of Neurology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China.
Background: Cilostazol is an antiplatelet drug and is used for stroke prevention and symptomatic peripheral vascular disease. Studies have reported the effects of cilostazol on cognitive function, but the results are inconsistent and have not been systematically assessed.
Methods: We systematically searched the PubMed, Embase, and Cochrane databases for relevant clinical studies.
Int J Mol Sci
December 2024
Department of Neurology, Medical University of Warsaw, 03-242 Warsaw, Poland.
Progressive supranuclear palsy (PSP) is a tauopathic atypical parkinsonian syndrome. Recent studies suggest that inflammation may play a role in PSP pathogenesis, highlighting markers like the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and cytokines such as IL-1β and IL-6. This study aimed to assess the relationship between peripheral inflammatory markers and psychological abnormalities in PSP-RS and PSP-P patients.
View Article and Find Full Text PDFTransfusion
December 2024
Laboratory of Cellular Hematology, DBCD, OBRR, CBER, FDA, Silver Spring, Maryland, USA.
Background: Pathogen reduction (PR) may be used as an alternative to gamma or x-ray irradiation (I) to prevent transfusion associated graft versus host disease (TA-GVHD) if the pathogen reduction technology has been shown to inactivate residual lymphocytes. However, as I is considered the gold standard for reducing the risk of TA-GVHD, some centers continue to perform I in addition to PR. This study investigated the effect of concurrent pathogen reduction and irradiation (PR/I) on the biochemical characteristics of apheresis platelets at day 1, 5, and 7 of storage at room temperature.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!